The therapeutic potential of host-specific and tumour-specific immune responses is well
recognized and, after many years, active immunotherapies directed at inducing or …

Faced with the challenges posed by infectious diseases and cancer, nucleic acid vaccines
present excellent prospects in clinical applications. Compared with traditional vaccines …

Advancements in human genomics over the last two decades have shown that cancer is
mediated by somatic aberration in the host genome. This discovery has incited enthusiasm …

DNA vaccination has emerged as an attractive immunotherapeutic approach against cancer
due to its simplicity, stability, and safety. Results from numerous clinical trials have …

Advances in basic immunology have led to an improved understanding of the interactions
between the immune system and tumours, generating renewed interest in approaches that …

Prostate cancer (PCa) is the most common cancer in men, and the second leading cause of
cancer related death in men in Western countries. The standard therapy for metastatic PCa …

Purpose Sipuleucel-T, the first FDA-approved autologous cellular immunotherapy for
treatment of advanced prostate cancer, is manufactured by activating peripheral blood …

Background Sipuleucel-T is a US Food and Drug Administration–approved immunotherapy
for asymptomatic or minimally symptomatic metastatic castration-resistant prostate cancer …

Among men treated with prostatectomy or radiation therapy for localized prostate cancer, the
state of an increasing prostate-specific antigen (PSA) level is known as biochemical …

It is becoming increasingly clear that virtually all types of human cancers harbor a small
population of stem-like cancer cells (ie, cancer stem cells, CSCs). These CSCs preexist in …